Syneos Health is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
The Leukemia & Lymphoma Society (LLS), transitioning to Blood Cancer United in August 2025, is a global nonprofit founded in 1949. It is dedicated to curing blood cancers and improving the quality of life for patients and their families. LLS is the largest voluntary health organization focused on blood cancer, having invested over $1.8 billion in research and serving a wide network of patients, caregivers, and healthcare professionals.
LLS's mission is to cure various blood cancers, including leukemia and lymphoma, while enhancing patient support. The organization is the largest nonprofit funder of blood cancer research, committing nearly $1.3 billion to advancements in immunotherapy and personalized medicine. LLS also provides free information, education, and support services to help patients navigate their diagnosis and treatment. Additionally, LLS advocates for improved access to care and increased research funding at both federal and state levels.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.